Home
Home

NewLink Genetics

NewLink Genetics Presents Preclinical Data on NLG919, a New Drug Candidate from a Novel Class of IDO Pathway Inhibitors for the Treatment of Cancer

NewLink Genetics Presents Preclinical Data on NLG919, a New Drug Candidate from a Novel Class of IDO Pathway Inhibitors for the Treatment of Cancer
Yahoo

Most Profitable Second Quarter Biotech Stocks

Most Profitable Second Quarter Biotech Stocks
TheStreet.com

NewLink Genetics Corporation: A Promising Immunotherapy Company With An Upcoming Catalyst

NewLink Genetics Corporation: A Promising Immunotherapy Company With An Upcoming Catalyst
Seeking Alpha

4 Small Biotech Stocks That Should Continue With Large Returns In 2013

4 Small Biotech Stocks That Should Continue With Large Returns In 2013
Seeking Alpha

Pharma IPOs Are Good Medicine

Pharma IPOs Are Good Medicine
TheStreet.com

The 10 biotech IPOs of 2011

The 10 biotech IPOs of 2011
Fierce Biotech

Cancer Drug Developer NewLink Genetics Gets Push From Analysts

Cancer Drug Developer NewLink Genetics Gets Push From Analysts
Minyanville

2012 Preview: Cancer Immunotherapy Catalysts

2012 Preview: Cancer Immunotherapy Catalysts
Seeking Alpha

3 Cancer Immunotherapy Biotechs With Catalysts For 2012

3 Cancer Immunotherapy Biotechs With Catalysts For 2012
Seeking Alpha

IPO Preview: NewLink Genetics

IPO Preview: NewLink Genetics
Seeking Alpha